Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

Franck-Emmanuel Nicolini, MD PhD, Stéphanie Désilets, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Vila, Stephane Morisset, Stat, Mohamad Sobh, PharmD, Mauricette Michallet, MD PhD, Valerie Dubois, MD

Blood (2018) 132 (Supplement 1): 5436.

https://doi.org/10.1182/blood-2018-99-117733

Published: 2018

Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Blood (2018) 132 (Supplement 1): 48.

https://doi.org/10.1182/blood-2018-99-113058

Published: 2018

Journal Articles

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Franck Emmanuel Nicolini, MD PhD, Vincent Alcazer, MD, Pascale Cony-Makhoul, MD PhD, Stephanie Dulucq, PhD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Liliana Villa, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2018) 132 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2018-99-113044

Published: 2018

Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Blood (2017) 130 (Supplement 1): 899.

https://doi.org/10.1182/blood.V130.Suppl_1.899.899

Published: 2017

Journal Articles

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Gaelle Fossard, MD, Vincent Alcazer, MD, Marie Balsat, MD, Helene Labussiere-Wallet, MD, Stephane Morisset, Stat, Mohamad Sobh, Isabelle Tigaud, MD, Pierre Sujobert, MD PhD, Mauricette Michallet, MD PhD, Franck Emmanuel Nicolini, MD PhD

Blood (2017) 130 (Supplement 1): 2900.

https://doi.org/10.1182/blood.V130.Suppl_1.2900.2900

Published: 2017

Journal Articles

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Franck Emmanuel Nicolini, MD PhD, Delphine Rea, MD, Vincent Alcazer, MD, Francoise Huguet, MD, Laurence Legros, MD PhD, Gaelle Fossard, MD, Elodie Grockowiak, PhD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Mohamad Sobh, Mauricette Michallet, MD PhD, Francois Parant, PharmD, Marie-Claude Gagnieu, PharmD

Blood (2017) 130 (Supplement 1): 2901.

https://doi.org/10.1182/blood.V130.Suppl_1.2901.2901

Published: 2017

Journal Articles

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Thomas Pagliardini, Franck E. Nicolini, MD PhD, Stephane Giraudier, MD PhD, Philippe Rousselot, Gabriel Etienne, MD PhD, Françoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Bruno R. Varet, MDPhD, Martine Escoffre, MD, Stephane Morisset, Stat, Francois-Xavier Mahon, Laurence Legros, MD PhD

Blood (2016) 128 (22): 788.

https://doi.org/10.1182/blood.V128.22.788.788

Published: 2016

Journal Articles

Tacrolimus Given As an Alternative to Cyclosporin after Allogeneic HSCT in Case of Renal Impairment: A Prospective Pilot Study

Marie Y Detrait, MD, Stéphane Morisset, Stat, Anne Beatrice Notarantonio, Pochon Cecile, Sabine Cohen, Catherine Rioufol, PharmD, Gabrielle Roth Guepin, Maud D'Aveni, Adele Dhuyser, Sylvie Tarillon, Chapel Valerie, Marie t Rubio, MDPhD, Barraco Fiorenza, Mauricette Michallet, MD PhD

Blood (2016) 128 (22): 5749.

https://doi.org/10.1182/blood.V128.22.5749.5749

Published: 2016

Journal Articles

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Franck E Nicolini, MD PhD, Vincent Alcazer, MD, Stephanie Dulucq, PharmD, PhD, Marie Balsat, MD, Helene Labussiere, MD, Helene Lequeu, MD, Mohamad Sobh, PharmD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Francois-Xavier Mahon, MD PhD, Gabriel Etienne, MD PhD

Blood (2016) 128 (22): 1893.

https://doi.org/10.1182/blood.V128.22.1893.1893

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different Outcomes

Stéphanie Ducreux, PharmD, Mohamad Sobh, PharmD, Stéphane Morisset, Stat, Marie Balsat, MD, Xavier Thomas, Caroline Lejeune, MD, Sophie Ducastelle-Leprêtre, MD, Fiorenza Barraco, MD, Hélène Labussière-wallet, MD, Franck E. Nicolini, MD PhD, Mauricette Michallet, MD PhD, Valérie Dubois, MD

Blood (2015) 126 (23): 5517.

https://doi.org/10.1182/blood.V126.23.5517.5517

Published: 2015

Journal Articles

Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study

Franck E. Nicolini, MD PhD, Mael Heiblig, MD, Stéphane Morisset, Stat, Denis Caillot, Valérie Coiteux, MD, Aude Charbonnier, MD, Françoise Huguet, MD, Viviane Dubruille, MD, Gabriel Etienne, MD PhD, Pascal Lenain, MD, Francois Guilhot, MD, Laurence Legros, MD, Philippe Rousselot, MD PhD, Shanti Amé, MD, Rémy DeFrance, MD, Jeremy Ruby, CRA, Francois-Xavier Mahon, MD PhD Professor, Delphine Rea

Blood (2015) 126 (23): 4039.

https://doi.org/10.1182/blood.V126.23.4039.4039

Published: 2015

Journal Articles

Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results

Blood (2015) 126 (23): 1578.

https://doi.org/10.1182/blood.V126.23.1578.1578

Published: 2015

Journal Articles

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Franck E. Nicolini, MD PhD, Marie Balsat, MD, Maud Lekieffre, MD, Vincent Alcazer, MD, Hélène Labussière-wallet, MD, Sarah Huet, PharmD, PhD, Sandrine Hayette, Stéphanie Dulucq, PharmD, PhD, Stéphane Morisset, Stat, Jeremy Ruby, CRA, Isabelle Tigaud, MD, Marie-Pierre Fort, CRA, Mael Heiblig, MD, Rémi Chapelon, CRA, Madeleine Etienne, CRA, Mohamad Sobh, PharmD, Francois-Xavier Mahon, MD PhD Professor, Mauricette Michallet, MD PhD, Gabriel Etienne, MD PhD

Blood (2015) 126 (23): 2774.

https://doi.org/10.1182/blood.V126.23.2774.2774

Published: 2015

Journal Articles

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Aline Praire, MSc, Frederic Garban, MD PhD, Claude Eric Bulabois, MD, Ibrahim Yakoub-Agha, MD PhD, Valerie Coiteux, MD, Remy Dulery, MD, Pierre-Simon Rohrlich, MDPhD, Faezeh Legrand, MD, Laurence Clement, Stephane Morisset, Stat., Giovanna Cannas, MD, Marie Y. Detrait, MD, Fiorenza Barraco, MD, Franck E. Nicolini, MD PhD, Olivier Hequet, MD

Blood (2014) 124 (21): 3916.

https://doi.org/10.1182/blood.V124.21.3916.3916

Published: 2014

Journal Articles

Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

Gaelle Fossard, MD, Emilie Blond, Pharm.D, Stephane Giraudier, MD PhD, Stephane Morisset, Stat., Jeremy Ruby, CRA student, Martine Escoffre-Barbe, MD, Hélène Labussière-Wallet, MD, Mael Heiblig, MD, Madeleine Etienne, CRA, Jocelyne Drai, Pharm.D, Mohamad Sobh, Pharm.M., Mauricette Michallet, MD PhD, Isabelle Redonnet-vernhet, MD PhD, Jean-christophe Lega, MD PhD, Gabriel Etienne, MD PhD, Franck E. Nicolini, MD PhD

Blood (2014) 124 (21): 3136.

https://doi.org/10.1182/blood.V124.21.3136.3136

Published: 2014

Journal Articles

Invasive Pulmonary Aspergillosis in AML and ALL Patients Hospitalized into an Intensive Care Unit Divided into 2 Areas with a Different Specific Air Environment: Evaluation of Posaconazole Prophylaxis and Comparison Between the Two Specific Air Environment Areas

Marie Y. Detrait, MD, Stephane Morisset, Stat., Jean-Pierre Delville, Arnaud Lixon, Sabine Meurisse, Xavier Holemans, Nathalie De Visscher, Philippe Mineur, MD, Delphine Pranger, Margareta Nedelcu, Julien Depaus, Martin Di Biase, Celine Van Wetter, Francoise Anckaert, Anne Kornreich, MD, Jean-Luc Canon

Blood (2014) 124 (21): 5260.

https://doi.org/10.1182/blood.V124.21.5260.5260

Published: 2014

Journal Articles

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Marie Y. Detrait, MD, Stephane Morisset, Stat., Jean-Pierre Delville, Arnaud Lixon, Julie Boul, Jean-François Colot, Sabine Meurisse, Odile Bocahut, Philippe Mineur, MD, Margareta Nedelcu, Delphine Pranger, Julien Depaus, Carmela Piacentini, Maryvonne Jurdan, MD, Anne Kornreich, MD, Jean-Luc Canon

Blood (2014) 124 (21): 5834.

https://doi.org/10.1182/blood.V124.21.5834.5834

Published: 2014

Journal Articles

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Franck E. Nicolini, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Mael Heiblig, MD, Emilie Blond, Pharm.D, Laurence Legros, MD, PhD, Yann Guillermin, MD, Stephane Morisset, Stat., Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Jeremy Ruby, CRA student, Mohamad Sobh, Pharm.M., Gaelle Richard-Colmant, MD, Celine Fettig, Tech., Mauricette Michallet, MD, PhD, Delphine Rea, MD, PhD

Blood (2013) 122 (21): 4020.

https://doi.org/10.1182/blood.V122.21.4020.4020

Published: 2013

Journal Articles

Significant Impact Of Iron Chelation After Allogeneic Hematopoetic Stem Cell Transplantation On Disease Recurrence: Potential Anti-Leukemic Activity

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Lila Gilis, MD, Richard Cohen, Tech., Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Colette Chapuis-Cellier, MD

Blood (2013) 122 (21): 180.

https://doi.org/10.1182/blood.V122.21.180.180

Published: 2013

Journal Articles

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Florence Beckerich, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Adriana Plesa, MD, Valerie Dubois, MD, Isabelle Mollet, Helene Labussiere, MD, Lila Gilis, MD, Sophie Ducastelle, MD, Oriane Le Borgne, CRA, Jeremy Monfray, CRA, Fiorenza Barraco, MD, Isabelle Tigaud, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 4639.

https://doi.org/10.1182/blood.V122.21.4639.4639

Published: 2013

NARROW

CP-CML Seems Related to Specific HLA Subtypes and the HLA DRB1 07 Allele Might Identify a Subgroup of Newly Diagnosed CP-CML Patients on Imatinib First-Line of Better Prognosis

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Deep Molecular Response in Imatinib First-Line 418 Newly Diagnosed CP CML Patients.

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Impact of Body Mass Index on Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib in First-Line

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge

Tacrolimus Given As an Alternative to Cyclosporin after Allogeneic HSCT in Case of Renal Impairment: A Prospective Pilot Study

Characterisation of Molecular Relapse Profiles after Tyrosine Kinase Inhibitor Cessation in Patients Eligible for Treatment-Free Remission Strategies in Chronic Phase CML

Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients in First Complete Remission: Significant Impact of the Interval Between Diagnosis and Transplantation on Different Outcomes

Ponatinib for Chronic Phase (CP) CML Failing Two or More Tyrosine Kinase Inhibitors (TKI) or Harboring a T315I Mutation in the Real Life: Pearl Observational Study

Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results

Very Long-Term Follow-up (> 80 months) of Imatinib (IM) First-Line for Chronic Phase (CP) CML Patients

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

Hyperhomocysteinemia and High Doses of Nilotinib Favour Cardio-Vascular Events in Chronic Phase Chronic Myelogenous Leukemia (CML) Patients

Invasive Pulmonary Aspergillosis in AML and ALL Patients Hospitalized into an Intensive Care Unit Divided into 2 Areas with a Different Specific Air Environment: Evaluation of Posaconazole Prophylaxis and Comparison Between the Two Specific Air Environment Areas

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Significant Impact Of Iron Chelation After Allogeneic Hematopoetic Stem Cell Transplantation On Disease Recurrence: Potential Anti-Leukemic Activity

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only